Miquel Armengot-Carbó1, Eduardo Nagore2, Zaida García-Casado3, Rafael Botella-Estrada4. 1. Department of Dermatology, Hospital General Universitari de Castelló [General University Hospital of Castelló], Castelló de la Plana, Spain; Universidad Cardenal Herrera-CEU [University Cardenal Herrera-CEU], CEU Universities, Castelló de la Plana, Spain. Electronic address: miquelarmengot@gmail.com. 2. Department of Dermatology, Instituto Valenciano de Oncología [Valencian Institute of Oncology], València, Spain; Universidad Católica de València San Vicente Ferrer [San Vicente Ferrer Catholic University of Valencia], València, Spain. 3. Laboratory of Molecular Biology, Instituto Valenciano de Oncología [Valencian Institute of Oncology], València, Spain. 4. Hospital Universitari i Politècnic La Fe [University and Polytechnic Hospital La Fe], València, Spain; Universitat de València [University of Valencia], València, Spain.
Abstract
BACKGROUND: The genetic basis of melanoma affects its clinicopathologic characteristics and increasingly influences its management. B-Raf proto-oncogene, serine/threonine kinase gene (BRAF)-mutated melanoma may present with specific dermoscopic features. OBJECTIVES: To identify the dermoscopic features associated with BRAF mutation in cutaneous melanoma and to evaluate a model capable of predicting BRAF mutations on the basis of dermoscopic and clinicopathologic features that are easily accessible in normal clinical practice. METHODS: A prospective, cross-sectional, observational, and descriptive study was performed. A total of 93 cutaneous melanomas with dermoscopic images from 93 patients were included. BRAF mutational status was determined by genetic analysis using 2 methods: cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Pleasanton, CA) and Sanger sequencing. Clinicopathologic data were collected; dermoscopic images were analyzed by 2 independent blind observers. RESULTS: Blue-white veil in dermoscopy was significantly associated with BRAF mutations (odds ratio, 4.3; 95% confidence interval, 1.6-11.5; P = .003). Patients with BRAF-mutated melanomas were significantly younger than those with wild-type melanomas (odds ratio, 0.96; 95% confidence interval, 0.93-0.99; P = .008). On the basis of these 2 variables, it was possible to predict BRAF mutational status in melanoma with 73% accuracy. LIMITATIONS: Histologic data were obtained from pathology reports. The accuracy of the predictive model has not been tested with a new data set. CONCLUSIONS: Blue-white veil in dermoscopy is associated with BRAF mutations in cutaneous melanoma.
BACKGROUND: The genetic basis of melanoma affects its clinicopathologic characteristics and increasingly influences its management. B-Raf proto-oncogene, serine/threonine kinase gene (BRAF)-mutated melanoma may present with specific dermoscopic features. OBJECTIVES: To identify the dermoscopic features associated with BRAF mutation in cutaneous melanoma and to evaluate a model capable of predicting BRAF mutations on the basis of dermoscopic and clinicopathologic features that are easily accessible in normal clinical practice. METHODS: A prospective, cross-sectional, observational, and descriptive study was performed. A total of 93 cutaneous melanomas with dermoscopic images from 93 patients were included. BRAF mutational status was determined by genetic analysis using 2 methods: cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Pleasanton, CA) and Sanger sequencing. Clinicopathologic data were collected; dermoscopic images were analyzed by 2 independent blind observers. RESULTS: Blue-white veil in dermoscopy was significantly associated with BRAF mutations (odds ratio, 4.3; 95% confidence interval, 1.6-11.5; P = .003). Patients with BRAF-mutated melanomas were significantly younger than those with wild-type melanomas (odds ratio, 0.96; 95% confidence interval, 0.93-0.99; P = .008). On the basis of these 2 variables, it was possible to predict BRAF mutational status in melanoma with 73% accuracy. LIMITATIONS: Histologic data were obtained from pathology reports. The accuracy of the predictive model has not been tested with a new data set. CONCLUSIONS: Blue-white veil in dermoscopy is associated with BRAF mutations in cutaneous melanoma.
Authors: Sarah Zhou; Daniel Sikorski; Honghao Xu; Andrei Zubarev; May Chergui; François Lagacé; Wilson H Miller; Margaret Redpath; Stephanie Ghazal; Marcus O Butler; Teresa M Petrella; Joël Claveau; Carolyn Nessim; Thomas G Salopek; Robert Gniadecki; Ivan V Litvinov Journal: Cancers (Basel) Date: 2021-05-10 Impact factor: 6.639